Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand
Issued Date
2022-09-01
Resource Type
eISSN
27134148
Scopus ID
2-s2.0-85137193266
Journal Title
Clinical and Experimental Pediatrics
Volume
65
Issue
9
Start Page
453
End Page
458
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical and Experimental Pediatrics Vol.65 No.9 (2022) , 453-458
Suggested Citation
Suwannaying K., Techavichit P., Komvilaisak P., Laoaroon N., Narkbunnam N., Sanpakit K., Chiengthong K., Chotsampancharoen T., Sathitsamitphong L., Santong C., Seksarn P., Hongeng S., Wiangnon S. Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand. Clinical and Experimental Pediatrics Vol.65 No.9 (2022) , 453-458. 458. doi:10.3345/cep.2022.00437 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85570
Title
Treatment outcomes of high-dose chemotherapy plus stem cell rescue in high-risk neuroblastoma patients in Thailand
Other Contributor(s)
Abstract
Background: In 2013, the Thai Pediatric Oncology Group (ThaiPOG) introduced a national protocol in which highdose chemotherapy plus stem cell rescue is performed without immunotherapy. Methods: This study aimed to elucidate the outcomes of high-risk neuroblastoma (HR-NB) patients treated with the ThaiPOG protocol. This retrospective cohort review included 48 patients (30 males, 18 females) with a median age of 3 years (range, 8 months to 18 years) who were treated at 5 ThaiPOG treatment centers in Thailand in 2000–2018. Results: Eight of the 48 patients showed MYCN amplification. Twenty-three patients (48%) received131I-meta-iodobenzylguanidine prior to high-dose chemotherapy and stem cell rescue. The majority of patients achieved a complete or very good response prior to consolidation treatment. The 5-year overall survival (OS) and event-free survival (EFS) rates were 45.1% and 40.4%, respectively. Patients aged >2 years had a nonsignificantly higher mortality risk (hazard ratio [HR], 2.66; 95% confidence interval [CI], 0.92–7.68; P=0.07). The MYCN amplification group had lower OS and EFS rates than the MYCN nonamplification group, but the difference was not statistically significant (45% OS and 37.5% EFS vs. 33.3% OS and 16.6% EFS; P=0.67 and P=0.67, respectively). Cisretinoic acid treatment for 12 months was a strong prognostic factor that could reduce mortality rates among HR-NB patients (HR, 0.27; 95%CI, 0.09–0.785; P=0.01). Conclusion: High-dose chemotherapy plus stem cell rescue followed by cis-retinoic acid for 12 months was well tolerated and could improve the survival rates of patients with HR-NB.